Brian T. Powl Net Worth

The estimated Net Worth of Brian T. Powl is at least $837 mil dollars as of 5 July 2023. Brian Powl owns over 3,854 units of Kura Oncology Inc stock worth over $817,982 and over the last 2 years Brian sold KURA stock worth over $18,769.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Brian Powl KURA stock SEC Form 4 insiders trading

Brian has made over 1 trades of the Kura Oncology Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Brian sold 3,854 units of KURA stock worth $18,769 on 5 July 2023.

The largest trade Brian's ever made was selling 3,854 units of Kura Oncology Inc stock on 5 July 2023 worth over $18,769. On average, Brian trades about 771 units every 0 days since 2022. As of 5 July 2023 Brian still owns at least 41,146 units of Kura Oncology Inc stock.

You can see the complete history of Brian Powl stock trades at the bottom of the page.

What's Brian Powl's mailing address?

Brian's mailing address filed with the SEC is C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA, 92130.

Insiders trading at Kura Oncology Inc

Over the last 6 years, insiders at Kura Oncology Inc have traded over $16,903,587 worth of Kura Oncology Inc stock and bought 50,000 units worth $575,000 . The most active insiders traders include Faheem Hasnain, Troy Edward Wilson, eMary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of $626,260. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth $57,922.

What does Kura Oncology Inc do?

at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.

Complete history of Brian Powl stock trades at Fate Therapeutics Inc e Kura Oncology Inc

Kura Oncology Inc executives and stock owners

Kura Oncology Inc executives and other stock owners filed with the SEC include:

• Kathleen Ford,
  Chief Operating Officer
• Troy Wilson,
  Chairman of the Board, President, Chief Executive Officer
• Marc Grasso,
  Chief Financial Officer and Chief Business Officer
• James Basta,
  Chief Legal Officer and Secretary
• Dr. Troy Edward Wilson,
  Chairman, CEO & Pres
• Dr. Troy Edward Wilson J.D., Ph.D.,
  Chairman, CEO, Pres & Principal Financial Officer
• Dr. Marc Grasso,
  CFO & Chief Bus. Officer
• Kathleen Ford,
  Chief Operating Officer
• Kirsten Flowers,
  Chief Commercial Officer
• Dr. Marc Grasso M.D.,
  Advisor
• Dr. Stephen Dale M.D.,
  Chief Medical Officer
• Diane Parks,
  Independent Director
• Robert Hoffman,
  Independent Director
• Faheem Hasnain,
  Lead Independent Director
• Thomas Malley,
  Independent Director
• Steven Stein,
  Independent Director
• Mary Szela,
  Independent Director
• Bridget Martell,
  Acting Chief Medical Officer
• Kirsten Flowers,
  Chief Commercial Officer
• Stephen Dale,
  Chief Medical Officer
• Thomas Doyle,
  Principal Accounting Officer & Sr. VP of Fin. and Accounting
• Dr. Nic G. Scalfarotto,
  Sr. VP of Regulatory Affairs
• Dr. Roger Bakale Ph.D.,
  VP and Head of CMC, Clinical & Commercial Manufacturing
• Teresa Brophy Bair Esq., J.D.,
  Chief Legal Officer & Corp. Sec.
• James E. Basta J.D., Esq.,
  Chief Compliance Officer & Corp. Sec.
• Pete De Spain,
  VP of Investor Relations & Corp. Communications
• Teresa Brophy Bair,
  Chief Legal Officer
• Antonio Gualberto,
  Head of Development & CMO
• Pingda Ren,
  SVP Chemistry&Pharma Sciences
• Annette North,
  SVP, General Counsel
• Carol Schafer,
  
• Helen Louise Collins,
  
• Brian T. Powl,
  Chief Commercial Officer
• Thomas James Doyle,
  SVP, Finance & Accounting